Publication | Closed Access

Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Breast OncologyHealth SciencesMedicinePharmacologyClinical TrialsBreast CancerPharmacotherapyFirst-line TreatmentCancer TreatmentOncologyRadiation OncologyEndocrine-related CancerAnastrozole Versus Placebo